NEWT ACQU Stock Nasdaq

NCACU

KYG6448C1116

Analysts' recommendations: NEWT ACQU

04-17

Top Midday Gainers

More recommendations

Newcourt Acquisition Corp. is a blank check company. The Company was formed for the purpose of effecting a merger, capital exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not identified any specific business combination target and has not, nor has anyone on behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. The Company has not commenced any operations and has not commenced any revenues.

Employees

Sector

More about the company

Market Cap	11.71M 10.23M 9.44M 8.7M 16.41M 1.13B 16.77M 113M 44.39M 552M 43.98M 43.01M 1.9B	P/E 2025	0.91x	P/E 2026	-0.2x
Enterprise Value	4.27M 3.73M 3.44M 3.17M 5.98M 411M 6.11M 41.11M 16.17M 201M 16.02M 15.67M 693M	EV / Sales 2025	-	EV / Sales 2026	-
Free-Float	-	Yield 2025 *	-	Yield 2026	-

06-22	Tranche Update on Psyence Biomedical Ltd.'s Equity Buyback Plan announced on January 12, 2026.	CI
06-22	Psyence Biomedical Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
04-24	FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain	MT
04-23	Psyence Biomedical Ltd. Initiates Patient Dosing In Phase IIb Trial Evaluating NPX-5 For Adjustment Disorder	CI
04-22	Top Premarket Decliners	MT
04-21	What to know about psychedelic therapies cited by Trump	RE
04-20	Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness	MT
04-17	Top Midday Gainers	MT
04-17	Psyence Biomedical Ltd Advances Nature-Derived Psilocybin And Ibogaine Therapies	CI
04-17	Top Premarket Gainers	MT
04-08	Psyence Biomedical Ltd Expands Australian Clinical Site Network And Advances NPX-5 Supported Clinical Activities	CI
03-03	Psyence Biomedical Ltd. Announces Export Of GMP-Manufactured Natural Psilocybin NPX-5 To Australia For Ongoing Phase IIb Clinical Trial	CI
03-03	Psyence Biomed announces export of GMP-manufactured natural psilocybin (NPX-5) to Australia for ongoing clinical trial phase IIb	RE

05-18	Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing	AQ
04-21	Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research	AQ
04-20	Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine	AQ
03-12	Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone	AQ
01-13	Psyence Biomedical : Interim Financials – September 30 2025	PU

	2025	2026
Net sales	-	-
Net income	1.01M 884K 816K 752K 1.42M 97.44M 1.45M 9.75M 3.84M 47.72M 3.8M 3.72M 164M	-6.94M -6.06M -5.59M -5.16M -9.72M -668M -9.93M -66.86M -26.3M -327M -26.05M -25.48M -1.13B
Net Debt	-6.14M -5.36M -4.95M -4.56M -8.6M -591M -8.79M -59.13M -23.26M -289M -23.04M -22.54M -996M	-7.44M -6.51M -6M -5.53M -10.43M -717M -10.66M -71.76M -28.22M -351M -27.96M -27.35M -1.21B

NEWT ACQU Stock Nasdaq

Stocks

NCACU

KYG6448C1116

Valuation: NEWT ACQU

Latest news : NEWT ACQU

Analysts' recommendations: NEWT ACQU

Press Releases: NEWT ACQU

Quotes and Performance

Financials

Company Profile